I agree and thats why investors call it """ SEEKING ALPO""""
It lets these clueless bloggers post more Dog DODO I will say this ,,,,,, the sentence structure is Quality Conjecture must be why Alpo published it.
We have several big Hedge funds piling into this stock so per this clown they must all be Stupid and just tossing bags of money down the flusher without any serious DD.
$200 PPS sound good to me ....................................... going down the tracks
pump pump pump up the volume
iLet see your a strong SELL ........... OK, that fine with me I love shorts for lots of reasons.
Stock liquidity requires a Higher volume short position, thats a good thing over the longterm investment Horizon.
The current available stock at the $7/$8 is limited so that dictates a higher stock price over the next month as Institutional buyers are not done accumulating IMO, their just starting to buy. The bigger funds have MKT CAP requirements of $500M so it will be up to the smaller investment funds and Hedge funds to push her up on all positive and anticipated NEWS. So this stockis only goes higher when P2b 1ST patient dosing is announced. $11/$12 PPs is on the Horizon
Sentiment: Strong Buy
Made it back to the $8's
Next stop $11/$12 range as 520 P1 trial starts dosing patients.
ARWR at this point is a momentum stock and will always trade up on anticipation of good pipeline news/progress.
My comment on shorts ........ interest not big enough to impact the PPS and an anticipated increase will add to the stocks liquidity. The bigger fund s want/like liquidity so I'm cheering for a bigger short position.
Stay focued on the Fund MM's continue increase in % of float. thats going to drive share price as the available daily trading float decreases and those clueless shorts than get trapped for a nice squeeze.
i also realize that Dirk has placed a $50 stock price target on positive P2a data with the caviat of it being a cure for HepB ............ Its biotech and We have all seen stocks go from $$5 to $50 overnight.
the street will be the final PPS price maker on ARWR
@$50 I will be a very rich content investor as I have a ton of ARWR in my Roth IRA
i will say this: pizzas 'PPS s numbers have levity to say it in a nice way.
proof of concept is P2b hitting the trial endpoint not P2a which has not even started yet.
A $60 stock price in 18 months is a big time significant move from $7.40
You sir are a classic pumper without the CL
i reckon some people just sit on their John Henry and can't get out of their own way by posting nothingism
your correct over the longterm but
pizza has it nailed in the short term next 30 days of trading does equate to a solid $8/$10 stock price
A1 is not the darkster.
read his informative posts on the Investor village board.
ANLY is in serious PPS bubble trouble. Its drug delivery program is still not proven to be safe over longterm dosing ............... premedicating with steroids not a good thing over the longterm. what side effects will a patient develop? HOW WILL STEROID USE IMPACT THE LONGTERM USE LABEL?
Thus Sales. To many open Questions.
another scenario could also play out after P2a Data. ARWR goes directly to a P2/P3 clinical trial with the intent of filing an NDA based on these Data.
If the P2a trial demonstrated no safety issues and a functional cure its a no brainer scenario. The gate would be ARWR would need to have longterm animal model safety data in hand.
let me put it another way
when we get P2a data in mid 2014 if positive the stock will pop 5 to 10 points on that event alone on top of the stock price run up to that event. P2b will be worth 20 points or more. Alnylam went from $6 to $60 in like 24 months on still a questional delivery platform when you take a close look under the hood like the premedication steroid factor.
a train???????? thata old investment thinking ...............................
Its a B1 bomber going down the runway getting ready for takeoff heading for the stratosphere with one huge investor payload.
On their way to a 5 by 18 scenario like ALNY's 5 by 15 .... 5 drugs in the clinic/P1 trials. As the pipeline moves forward over next 4 years IMO its a no-brainer we will out perform ALNY on a MKT CAP Basis.
Sentiment: Strong Buy
When we get P2b results for HepB most likely 2H/15......... PPS will explode towards $100 if Dirk is correct on his $50 PT based on P2a results. We will see one of the largest $$$ drug partnerships in dsiRNAi history.
Expanding the pipeline will also be important to investment community. ARWR needs to execute on another RNAi drug into the clinic in 2014 and do a repeat in 2015, This stock will be than be priced by the street like alnylam on steroids.
Sentiment: Strong Buy